BR0013113A - Piridazinas substituìdas e piridazinas fundidas com atividade inibidora da angiogênese - Google Patents

Piridazinas substituìdas e piridazinas fundidas com atividade inibidora da angiogênese

Info

Publication number
BR0013113A
BR0013113A BR0013113-0A BR0013113A BR0013113A BR 0013113 A BR0013113 A BR 0013113A BR 0013113 A BR0013113 A BR 0013113A BR 0013113 A BR0013113 A BR 0013113A
Authority
BR
Brazil
Prior art keywords
pyridazines
substituted
fused
angiogenesis
inhibiting activity
Prior art date
Application number
BR0013113-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Jacques P Dumas
Holia N Hatoum-Mokdad
Teddy Kite Joe
Harold C E Kluender
Wendy Lee
Dhanapalan Nagarathnam
Robert N Sibley
Ning Su
Stephen James Boyer
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of BR0013113A publication Critical patent/BR0013113A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
BR0013113-0A 1999-08-10 2000-08-08 Piridazinas substituìdas e piridazinas fundidas com atividade inibidora da angiogênese BR0013113A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37132299A 1999-08-10 1999-08-10
PCT/US2000/021579 WO2001010859A1 (en) 1999-08-10 2000-08-08 Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity

Publications (1)

Publication Number Publication Date
BR0013113A true BR0013113A (pt) 2002-04-30

Family

ID=23463486

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0013113-0A BR0013113A (pt) 1999-08-10 2000-08-08 Piridazinas substituìdas e piridazinas fundidas com atividade inibidora da angiogênese

Country Status (19)

Country Link
EP (1) EP1208096B1 (enExample)
JP (1) JP2003506447A (enExample)
KR (1) KR20020019969A (enExample)
CN (1) CN1378543A (enExample)
AR (1) AR025068A1 (enExample)
AT (1) ATE265448T1 (enExample)
AU (1) AU775237B2 (enExample)
BR (1) BR0013113A (enExample)
CA (1) CA2381621A1 (enExample)
CO (1) CO5180637A1 (enExample)
DE (1) DE60010280T2 (enExample)
ES (1) ES2219382T3 (enExample)
IL (1) IL147885A0 (enExample)
MX (1) MXPA02001324A (enExample)
NO (1) NO20020569L (enExample)
NZ (1) NZ517087A (enExample)
PE (1) PE20010494A1 (enExample)
WO (1) WO2001010859A1 (enExample)
ZA (1) ZA200200691B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6689883B1 (en) 1999-09-28 2004-02-10 Bayer Pharmaceuticals Corporation Substituted pyridines and pyridazines with angiogenesis inhibiting activity
AR025752A1 (es) * 1999-09-28 2002-12-11 Bayer Corp Piridinas y piridacinas sustituidas con actividad de inhibicion de angiogenesis
US7977333B2 (en) 2000-04-20 2011-07-12 Bayer Healthcare Llc Substituted pyridines and pyridazines with angiogenesis inhibiting activity
GB0111078D0 (en) 2001-05-04 2001-06-27 Novartis Ag Organic compounds
EP1712234B1 (en) * 2001-09-12 2009-01-28 Novartis AG Use of 4-Pyridylmethylphthalazines for Renal Cancer Treatment
CA2471314A1 (en) * 2001-12-21 2003-07-24 Bayer Pharmaceuticals Corporation Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives
AU2003249369A1 (en) * 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
CN100372535C (zh) * 2002-09-24 2008-03-05 诺瓦提斯公司 4-吡啶基甲基-酞嗪衍生物在制备治疗骨髓增生异常综合征的药物中的用途
AU2003288034A1 (en) * 2002-11-12 2004-06-03 Novartis Ag Treatment of mesothelioma
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
ES2470341T3 (es) 2007-04-05 2014-06-23 Amgen, Inc Moduladores de la aurora cinasa y método de uso
PL2167549T3 (pl) 2007-06-19 2013-03-29 Rynel Inc Materiały zawierające cząstki polimeru rozpuszczalnego w wodzie oraz sposoby ich wytwarzania i stosowania
AU2009226024B2 (en) 2008-03-20 2012-07-12 Amgen Inc. Aurora kinase modulators and method of use
CA2732101C (en) * 2008-08-04 2013-09-17 Amgen Inc. Aurora kinase modulators and methods of use
WO2010019473A1 (en) 2008-08-14 2010-02-18 Amgen Inc. Aurora kinase modulators and methods of use
CN117355303A (zh) * 2021-01-28 2024-01-05 佛罗里达大学研究基金会公司 化合物及其用于治疗神经退行性、退行性和代谢病症的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1293565A (en) * 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
JPH03106875A (ja) * 1989-09-20 1991-05-07 Morishita Pharmaceut Co Ltd １―（３―ピリジルメチル）フタラジン誘導体
JPH0673022A (ja) * 1992-08-27 1994-03-15 Kumiai Chem Ind Co Ltd ピリミジンまたはトリアジン誘導体及び除草剤
EP0722936B1 (en) * 1994-08-09 2004-05-19 Eisai Co., Ltd. Fused pyridazine compound
JP3919835B2 (ja) * 1994-08-09 2007-05-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 縮合ピリダジン系化合物
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
ATE329596T1 (de) * 1999-03-30 2006-07-15 Novartis Pharma Gmbh Phthalazinderivate zur behandlung von entzündlicher erkrankungen

Also Published As

Publication number Publication date
AU775237B2 (en) 2004-07-22
ES2219382T3 (es) 2004-12-01
NO20020569L (no) 2002-04-10
DE60010280D1 (de) 2004-06-03
MXPA02001324A (es) 2002-07-22
CO5180637A1 (es) 2002-07-30
ATE265448T1 (de) 2004-05-15
JP2003506447A (ja) 2003-02-18
NZ517087A (en) 2004-05-28
AU6895400A (en) 2001-03-05
CA2381621A1 (en) 2001-02-15
EP1208096A1 (en) 2002-05-29
IL147885A0 (en) 2002-08-14
AR025068A1 (es) 2002-11-06
EP1208096B1 (en) 2004-04-28
KR20020019969A (ko) 2002-03-13
ZA200200691B (en) 2003-10-29
NO20020569D0 (no) 2002-02-05
PE20010494A1 (es) 2001-06-27
CN1378543A (zh) 2002-11-06
WO2001010859A1 (en) 2001-02-15
DE60010280T2 (de) 2009-10-15

Similar Documents

Publication Publication Date Title
BRPI0014382B8 (pt) piridinas e piridazinas substituídas com atividade de inibição de angiogênese bem como composições farmacêuticas compreendendo os mesmos
BR9810137A (pt) Composto, composição farmacêutica e método de tratamento ou prevenção de uma desordem tromoboembólica
WO2001019798A3 (en) Inhibitors of factor xa
DE60040676D1 (de) BENZAMIDE UND ÄHNLICHE INHIBITOREN VON FAKTOR Xa
WO2000071510A3 (en) INHIBITORS OF FACTOR Xa
NO953967L (no) Indolderivater som 5-HT1A og/eller 5-HT2 ligander
NO904209L (no) Fremgangsmaate for fremstilling av n-aminokarbamater relatert til fysostigmin, og deres anvendelse som medikamenter.
BR9803497A (pt) Compostos, composições farmacêuticas, e processos para preparar os compostos e as composições e para tratar distúrbio do sistema nervoso central.
FI940229A0 (fi) Trisykliset kondensoituneet heterosykliset yhdisteet, niiden valmistus ja käyttö
FR2674856B1 (fr) Nouveaux antihistaminiques non sedatifs, derives de benzimidazole, leur procede de preparation et leur utilisation en tant que medicaments.
ES2196308T3 (es) Derivado de 2-cianoiminoimidazol que inhiben la pde iv.
BR9811557A (pt) Derivados do 2-)4-aril ou heteroaril-piperazin-1-ilmetil)-1h-indol
NO975681L (no) Benzisoxazol- og indazol-derivater som antipsykotiske midler
NO923686D0 (no) Substituerte pyridinylamino-1h-indoler, 1h-indazoler, 2h-indazoler, benzo(b)-thiofener og 1,2-benzisotiazoler, en fremgangsmaate for deres fremstilling og deres anvendelse som legemidler
RU93045711A (ru) Нейролептические пергидро-1h-пиридо(1,2-a)пиразины, способ их получения, фармацевтическая композиция, способ лечения
BR9814188A (pt) "agonistas de 5-ht1f"
YU120290A (sh) Novi derivati r(-)3-kinuklidinola
NO995594D0 (no) Nye substituerte heterocykliske forbindelser, fremgangsmåte ved deres fremstilling og farmasöytiske sammensetninger inneholdende dem
FI964436A0 (fi) Uudet hydroksiimijohdannaiset, niitä sisältävät farmaseuttiset koostumukset sekä menetelmä niiden valmistamiseksi
DE60003671D1 (de) Halo-derivate von 9-deoxo-9a-aza-9a-homerythromycin a
CA2334012A1 (en) 2-aminopyridines containing fused ring substituents as nitric oxide synthase inhibitors
DE69701381D1 (de) Peptid-aldehydderivate als antikoagulierende mittel
ES2173993T3 (es) Derivados de piperidina.
JO2031B1 (en) Invention title:
UY34283A (es) Piridacinas sustituidas con actividad de inhibición de angiogénesis

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A, 8A E 9A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2008 DE 30/06/2009.